April 16, 2024
RegMed Investors (RMi) Closing Bell: declining threads extend
April 11, 2024
RegMed Investors (RMi) Closing Bell: sector seeps, although with subdued selling
April 10, 2024
RegMed Investors (RMi) Closing Bell: the cell and gene therapy sector got chewed-up, bloods everywhere
April 8, 2024
RegMed Investors (RMi) Closing Bell: what’s moving the sector?
April 5, 2024
RegMed Investors (RMi) Closing Bell: economic circumstances drove a 5 session/weekly downside
April 4, 2024
RegMed Investors (RMi) Closing Bell: economics undermine sector’s share pricing before jobs report
April 3, 2024
RegMed Investors (RMi) Closing Bell: The switch is still flipped
April 2, 2024
RegMed Investors (RMi) Closing Bell: weakness is more of a wipe-out
April 1, 2024
RegMed Investors (RMi) Closing Bell: An early share pricing eclipse in first session of April?
March 29, 2024
RegMed Investors (RMi) Closing Bell: done and over, portfolios escaped bloodied but, relatedly intact
March 27, 2024
RegMed Investors (RMi) Closing Bell: The anxiousness of the session was abrogated with a risk appetite satisfied
March 26, 2024
RegMed Investors (RMi) Closing Bell: a negative sector close
March 25, 2024
RegMed Investors (RMi) Closing Bell: twists and turns as Monday closes barely positive and a coming end of March and Q1/24
March 22, 2024
RegMed Investors (RMi) Closing Bell: A question had been asked, are there legs to the sector?
March 21, 2024
RegMed Investors (RMi) Closing Bell: The cell and gene therapy sector faltered
March 19, 2024
RegMed Investors (RMi) Closing Bell: Short-volatility based trades or actual sentiment shaping?
March 18, 2024
RegMed Investors (RMi) Closing Bell: a session of cell and gene therapy sector shifting share pricing
March 15, 2024
RegMed Investors (RMi) Closing Bell: triple witching Friday
March 13, 2024
RegMed Investors (RMi) Closing Bell: drop and give me push-ups, I’ll count until the PPI and jobless claims numbers order
March 12, 2024
RegMed Investors (RMi) Closing Bell: fresh inflation “number” upset daily share pricing response
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.